Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 760734, 9 pages
http://dx.doi.org/10.1155/2014/760734
Review Article

HIV Treatment as Prevention: Contradictory Perspectives from Dynamic Mathematical Models

1National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155 Changbai Road, Beijing 102206, China
2School of Agroforestry and Medicine, The Open University of China, Beijing 100039, China
3Department of Preventive Medicine, School of Medicine, Vanderbilt University, Nashville, TN 37232, USA

Received 15 June 2014; Accepted 26 November 2014; Published 15 December 2014

Academic Editor: Esteban Martinez

Copyright © 2014 Jing Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. Anderson, S. Gupta, and R. M. May, “Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1,” Nature, vol. 350, no. 6316, pp. 356–359, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. S. M. Blower, H. B. Gershengorn, and R. M. Grant, “A tale of two futures: HIV and antiretroviral therapy in San Francisco,” Science, vol. 287, no. 5453, pp. 650–654, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. J. X. Velasco-Hernandez, H. B. Gershengorn, and S. M. Blower, “Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?” Lancet Infectious Diseases, vol. 2, no. 8, pp. 487–493, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Blower, A. N. Aschenbach, H. B. Gershengorn, and J. O. Kahn, “Predicting the unpredictable: transmission of drug-resistant HIV,” Nature Medicine, vol. 7, no. 9, pp. 1016–1020, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Blower, L. Ma, P. Farmer, and S. Koenig, “Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance,” Current Drug Targets—Infectious Disorders, vol. 3, no. 4, pp. 345–353, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. S. M. Blower, A. N. Aschenbach, and J. O. Kahn, “Predicting the transmission of drug-resistant HIV: comparing theory with data,” The Lancet Infectious Diseases, vol. 3, no. 1, pp. 10–11, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. WHO, “Report on the global HIV/AIDS epidemic 2002,” 2002, http://www.who.int/hiv/pub/me/pubepidemic2002/en/.
  8. J. S. Montaner, V. D. Lima, R. Barrios et al., “Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study,” The Lancet, vol. 376, no. 9740, pp. 532–539, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Attia, M. Egger, M. Müller, M. Zwahlen, and N. Low, “Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis,” AIDS, vol. 23, no. 11, pp. 1397–1404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Donnell, J. M. Baeten, J. Kiarie et al., “Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis,” The Lancet, vol. 375, no. 9731, pp. 2092–2098, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Marks, N. Crepaz, J. W. Senterfitt, and R. S. Janssen, “Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: Implications for HIV prevention programs,” Journal of Acquired Immune Deficiency Syndromes, vol. 39, no. 4, pp. 446–453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ray, R. Logan, J. Sterne et al., “The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals,” AIDS, vol. 24, no. 1, pp. 123–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M.-C. Boily, F. I. Bastos, K. Desai, and B. Mâsse, “Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models,” Sexually Transmitted Diseases, vol. 31, no. 2, pp. 100–112, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. D. P. Wilson, “HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention,” PLoS Medicine, vol. 9, no. 7, Article ID e1001231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. S. Cohen, Y. Q. Chen, M. McCauley et al., “Prevention of HIV-1 infection with early antiretroviral therapy,” The New England Journal of Medicine, vol. 365, no. 6, pp. 493–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. S. Cohen, C. Dye, C. Fraser, W. C. Miller, K. A. Powers, and B. G. Williams, “HIV treatment as prevention: debate and commentary—will early infection compromise treatment-as-prevention strategies?” PLoS Medicine, vol. 9, no. 7, Article ID e1001232, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Meyer-Rath and M. Over, “HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions,” PLoS Medicine, vol. 9, no. 7, Article ID e1001247, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. WHO, UNAIDS, and UNICEF, Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access: Progress Report 2011, WHO Press, Geneva, Switzerland, 2011.
  19. K. J. Rothman, S. Greenland, and T. L. Lash, Modern Epidemiology, Lippincott Williams & Wilkins, Riverwoods, Ill, USA, 3rd edition, 2008.
  20. E. J. Amundsen, H. Stigum, J.-A. Røttingen, and O. O. Aalen, “Definition and estimation of an actual reproduction number describing past infectious disease transmission: application to HIV epidemics among homosexual men in Denmark, Norway and Sweden,” Epidemiology and Infection, vol. 132, no. 6, pp. 1139–1149, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. R. M. Granich, C. F. Gilks, C. Dye, K. M. de Cock, and B. G. Williams, “Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model,” The Lancet, vol. 373, no. 9657, pp. 48–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. The HIV-CAUSAL Collaboration, “The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals,” AIDS, vol. 24, no. 1, pp. 123–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. T. C. Quinn, M. J. Wawer, N. Sewankambo et al., “Viral load and heterosexual transmission of human immunodeficiency virus type 1,” The New England Journal of Medicine, vol. 342, no. 13, pp. 921–929, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. P. J. Dodd, G. P. Garnett, and T. B. Hallett, “Examining the promise of HIV elimination by “test and treat” in hyperendemic settings,” AIDS, vol. 24, no. 5, pp. 729–735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. R. F. Baggaley, G. P. Garnett, and N. M. Ferguson, “Modelling the impact of antiretroviral use in resource-poor settings,” PLoS Medicine, vol. 3, no. 4, article e124, pp. 493–504, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. W. Eaton, L. F. Johnson, J. A. Salomon et al., “HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa,” PLoS Medicine, vol. 9, no. 7, Article ID e1001245, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. U. L. Abbas, R. Glaubius, A. Mubayi, G. Hood, and J. W. Mellors, “Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa,” Journal of Infectious Diseases, vol. 208, no. 2, pp. 224–234, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Cremin, R. Alsallaq, M. Dybul, P. Piot, G. Garnett, and T. B. Hallett, “The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis,” AIDS, vol. 27, no. 3, pp. 447–458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. K. A. Powers, A. C. Ghani, W. C. Miller et al., “The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study,” The Lancet, vol. 378, no. 9787, pp. 256–268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Xiridou, R. Geskus, J. De Wit, R. Coutinho, and M. Kretzschmar, “Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men,” AIDS, vol. 18, no. 9, pp. 1311–1320, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Granich, J. G. Kahn, R. Bennett et al., “Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050,” PLoS ONE, vol. 7, no. 2, p. e30216, 2012. View at Google Scholar
  32. D. P. Wilson, A. Hoare, D. G. Regan, and M. G. Law, “Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men,” Sexual Health, vol. 6, no. 1, pp. 19–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Xiridou, R. Geskus, J. De Wit, R. Coutinho, and M. Kretzschmar, “The contribution of steady and casual partnerships to the incidence of HIV infection among homosexual men in Amsterdam,” AIDS, vol. 17, no. 7, pp. 1029–1038, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. W. Delva, J. W. Eaton, F. Meng et al., “HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes,” PLoS Medicine, vol. 9, no. 7, Article ID e1001258, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Bezemer, F. de Wolf, M. C. Boerlijst, A. van Sighem, T. D. Hollingsworth, and C. Fraser, “27 years of the HIV epidemic amongst men having sex with men in the Netherlands: an in depth mathematical model-based analysis,” Epidemics, vol. 2, no. 2, pp. 66–79, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Kato, R. Granich, D. D. Bui et al., “The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission,” Journal of Acquired Immune Deficiency Syndromes, vol. 63, no. 5, pp. e142–e149, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. V. D. Lima, K. Johnston, R. S. Hogg et al., “Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic,” Journal of Infectious Diseases, vol. 198, no. 1, pp. 59–67, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Bärnighausen, D. E. Bloom, and S. Humair, “Economics of antiretroviral treatment vs. circumcision for HIV prevention,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 52, pp. 21271–21276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Schwartländer, J. Stover, T. Hallett et al., “Towards an improved investment approach for an effective response to HIV/AIDS,” The Lancet, vol. 377, no. 9782, pp. 2031–2041, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. R. T. Gray, L. Zhang, T. Lupiwa, and D. P. Wilson, “Forecasting the population-level impact of reductions in HIV antiretroviral therapy in Papua new guinea,” AIDS Research and Treatment, vol. 2011, Article ID 891593, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. B. G. Wagner and S. Blower, “Universal access to HIV treatment versus universal “test and treat”: transmission, drug resistance & treatment costs,” PLoS ONE, vol. 7, no. 9, Article ID e41212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. E. F. Long, M. L. Brandeau, and D. K. Owens, “The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States,” Annals of Internal Medicine, vol. 153, no. 12, pp. 778–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. E. D. Charlebois, M. Das, T. C. Porco, and D. V. Havlir, “The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in san francisco,” Clinical Infectious Diseases, vol. 52, no. 8, pp. 1046–1049, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Xu, Y. Xiao, and N. Wang, “Modeling sexual transmission of HIV/AIDS in Jiangsu province, China,” Mathematical Methods in the Applied Sciences, vol. 36, no. 2, pp. 234–248, 2013. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  45. E. Tchetgen, E. H. Kaplan, and G. H. Friedland, “Public health consequences of screening patients for adherence to highly active antiretroviral therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 26, no. 2, pp. 118–129, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. R. P. Walensky, A. D. Paltiel, E. Losina et al., “Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC,” Clinical Infectious Diseases, vol. 51, no. 4, pp. 392–400, 2010. View at Google Scholar
  47. M. K. Smith, K. A. Powers, K. E. Muessig, W. C. Miller, and M. S. Cohen, “HIV treatment as prevention: the utility and limitations of ecological observation,” PLoS Medicine, vol. 9, no. 7, Article ID e1001260, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. B. G. Wagner and S. Blower, “Voluntary universal testing and treatment is unlikely to lead to HIV elimination: a modeling analysis,” 2009, http://precedings.nature.com/documents/3917/version/1/.
  49. V. Cambiano, S. Bertagnolio, M. R. Jordan, J. D. Lundgren, and A. Phillips, “Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings,” Journal of Infectious Diseases, vol. 207, no. 2, pp. S57–S62, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Sood, Z. Wagner, A. Jaycocks, E. Drabo, and R. Vardavas, “Test-and-treat in los angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County,” Clinical Infectious Diseases, vol. 56, no. 12, pp. 1789–1796, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. V. Supervie, J. G. García-Lerma, W. Heneine, and S. Blower, “HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 27, pp. 12381–12386, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Estill, C. Aubrière, M. Egger et al., “Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis,” AIDS, vol. 26, no. 11, pp. 1403–1413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. U. L. Abbas, R. M. Anderson, and J. W. Mellors, “Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings,” PLoS ONE, vol. 2, article e875, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. U. L. Abbas, G. Hood, A. W. Wetzel, and J. W. Mellors, “Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP),” PLoS ONE, vol. 6, no. 4, Article ID e18165, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. B. E. Nichols, C. A. B. Boucher, J. H. van Dijk et al., “Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study,” PLoS ONE, vol. 8, no. 3, Article ID e59549, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Hoare, S. J. Kerr, K. Ruxrungtham et al., “Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia,” PLoS ONE, vol. 5, no. 6, Article ID e10981, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. A. J. Marks, D. Pillay, and A. R. McLean, “The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns,” Journal of Theoretical Biology, vol. 262, no. 1, pp. 1–13, 2010. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  58. J. Goudsmit, G. J. Weverling, L. van der Hoek et al., “Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains,” AIDS, vol. 15, no. 17, pp. 2293–2301, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. B. G. Williams, E. Gouws, J. Hargrove, C. van Schalkwyk, and H. Brand, “Pre-exposure prophylaxis (PrEP) versus treatment-as-prevention (TasP) for the control of HIV: where does the balance lie?” http://arxiv.org/abs/1209.0364.
  60. N. C. Levy, R. A. Miksad, and O. T. Fein, “From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa,” Journal of Urban Health, vol. 82, no. 3, pp. 498–509, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. Médecins sans Frontières South Africa, Department of Public Health at the University of Cape Town, and Provincial Administration of the Western Cape SA, Antiretroviral Therapy in Primary Health Care: Experience of the Khayelitsha Programme in South Africa, World Health Organization, 2003.
  62. J. Li, S. Gilmour, H. Zhang, A. Koyanagi, and K. Shibuya, “The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs,” AIDS, vol. 26, no. 16, pp. 2069–2078, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. S. W. Sorensen, S. L. Sansom, J. T. Brooks et al., “A mathematical model of comprehensive test-and-treat services and HIV incidence among men who have sex with men in the United States,” PLoS ONE, vol. 7, no. 2, Article ID e29098, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. L. Zhang, R. T. Gray, and D. P. Wilson, “Modelling the epidemiological impact of scaling up HIV testing and antiretroviral treatment in China,” Sexual Health, vol. 9, no. 3, pp. 261–271, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. P. van de Ven, P. Rawstorne, J. Crawford, and S. Kippax, “Increasing proportions of Australian gay and homosexually active men engage in unprotected anal intercourse with regular and with casual partners,” AIDS Care, vol. 14, no. 3, pp. 335–341, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Van Sighem, I. Jansen, D. Bezemer et al., “Increasing sexual risk behaviour among Dutch men who have sex with men: mathematical models versus prospective cohort data,” AIDS, vol. 26, no. 14, pp. 1840–1843, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. M. G. Law, G. Prestage, A. Grulich, P. van de Ven, and S. Kippax, “Modelling HIV incidence in gay men: Increased treatment, unsafe sex and sexually transmissible infections,” AIDS, vol. 16, no. 3, pp. 499–501, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. M. G. Law, G. Prestage, A. Grulich, P. Van de Ven, and S. Kippax, “Modelling the effect of combination antiretroviral treatments on HIV incidence,” AIDS, vol. 15, no. 10, pp. 1287–1294, 2001. View at Publisher · View at Google Scholar · View at Scopus
  69. R. A. Alsallaq, J. M. Baeten, C. L. Celum et al., “Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community,” PLoS ONE, vol. 8, no. 1, Article ID e54575, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Bezemer, F. de Wolf, M. C. Boerlijst et al., “A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy,” AIDS, vol. 22, no. 9, pp. 1071–1077, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Britton and D. Lindenstrand, “Epidemic modelling: aspects where stochasticity matters,” Mathematical Biosciences, vol. 222, no. 2, pp. 109–116, 2009. View at Publisher · View at Google Scholar · View at Zentralblatt MATH · View at MathSciNet · View at Scopus
  72. D. P. Word, D. A. T. Cummings, D. S. Burke, S. Iamsirithaworn, and C. D. Laird, “A nonlinear programming approach for estimation of transmission parameters in childhood infectious disease using a continuous time model,” Journal of the Royal Society Interface, vol. 9, no. 73, pp. 1983–1987, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. W. Delva, D. P. Wilson, L. Abu-Raddad, M. Gorgens, T. B. Hallett, and A. Welte, “HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation,” PLoS Medicine, vol. 9, no. 7, Article ID e1001239, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group, “HIV treatment as prevention: models, data, and questions—towards evidence-based decision-making,” PLoS Medicine, vol. 9, no. 7, Article ID e1001259, 2012. View at Google Scholar
  75. F. Brauer, “Mathematical epidemiology is not an oxymoron,” BMC Public Health, vol. 9, supplement 1, article S2, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. U. L. Abbas, R. M. Anderson, and J. W. Mellors, “Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings,” Journal of Acquired Immune Deficiency Syndromes, vol. 41, no. 5, pp. 632–641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Song, T. Feng, M. Bulterys et al., “An integrated city-driven perinatal HIV prevention program covering 1.8 million pregnant women in shenzhen, China, 2000 to 2010,” Sexually Transmitted Diseases, vol. 40, no. 4, pp. 329–334, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. J. M. Baeten, D. Donnell, P. Ndase et al., “Antiretroviral prophylaxis for HIV prevention in heterosexual men and women,” The New England Journal of Medicine, vol. 367, no. 5, pp. 399–410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. R. M. Grant, J. R. Lama, P. L. Anderson et al., “Preexposure chemoprophylaxis for HIV prevention in men who have sex with men,” The New England Journal of Medicine, vol. 363, no. 27, pp. 2587–2599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. Q. A. Karim, S. S. A. Karim, J. A. Frohlich et al., “Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women,” Science, vol. 329, no. 5996, pp. 1168–1174, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. M. C. Thigpen, P. M. Kebaabetswe, L. A. Paxton et al., “Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana,” The New England Journal of Medicine, vol. 367, no. 5, pp. 423–434, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Pappas, Y. Jia, and O. A. Khan, Three Decades of HIV/AIDS, Medscape Public Health, 2011.
  83. “HIV in the United States: The Stage of Care,” http://www.cdc.gov/nchhstp/newsroom/docs/HIV-Stages-of-Care-Factsheet-508.pdf.
  84. CDC, “Using Viral Load Data to Monitor HIV Burden and Treatment Outcomes in the United States,” http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/viral_load.htm.
  85. Prevention Benefits of HIV Treatment, http://www.cdc.gov/hiv/prevention/research/tap/index.html.
  86. S. M. Cohen, M. M. van Handel, B. M. Branson et al., “Vital signs: HIV prevention through care and treatment—United States,” Morbidity and Mortality Weekly Report, vol. 60, no. 47, pp. 1618–1623, 2011. View at Google Scholar · View at Scopus
  87. A. Pecoraro, C. Royer-Malvestuto, B. Rosenwasser et al., “Factors contributing to dropping out from and returning to HIV treatment in an inner city primary care HIV clinic in the United States,” AIDS Care: Psychological and Socio-medical Aspects of AIDS/HIV, vol. 25, no. 11, pp. 1399–1406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. N. E. Chen, J. E. Gallant, and K. R. Page, “A systematic review of HIV/AIDS survival and delayed diagnosis among Hispanics in the United States,” Journal of Immigrant and Minority Health, vol. 14, no. 1, pp. 65–81, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. O. W. Fong, C. F. Ho, L. Y. Fung et al., “Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients,” HIV Medicine, vol. 4, no. 2, pp. 133–138, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. X. Wang, L. Yang, H. Li et al., “Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China,” Current HIV Research, vol. 9, no. 2, pp. 103–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Li, H. Li, L. Li et al., “Prevalence and evolution of drug resistance HIV-1 variants in Henan, China,” Cell Research, vol. 15, no. 11, pp. 843–849, 2005. View at Google Scholar
  92. L. Rong, Z. Feng, and A. S. Perelson, “Emergence of HIV-1 drug resistance during antiretroviral treatment,” Bulletin of Mathematical Biology, vol. 69, no. 6, pp. 2027–2060, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Liu, L. G. Miller, R. D. Hays et al., “Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors,” Journal of Acquired Immune Deficiency Syndromes, vol. 41, no. 3, pp. 315–322, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. T. A. Rasmussen, M. Tolstrup, A. Winckelmann, L. Østergaard, and O. S. Søgaard, “Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials,” Human Vaccines and Immunotherapeutics, vol. 9, no. 4, pp. 790–799, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. C. Katlama, S. G. Deeks, B. Autran et al., “Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs,” The Lancet, vol. 381, no. 9883, pp. 2109–2117, 2013. View at Publisher · View at Google Scholar · View at Scopus